US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.16 against a street estimate of 0.15 — a beat of 6.7%.
Analysts rate Stevanato Group SpA a buy (9 buy, 5 hold, 0 sell out of 14) with an average price target of $24.47.
CONFIDENT STVN delivered Q2 revenue growth of 8% YoY to €302M with 26% adjusted EBITDA margin. High-value solutions grew 16%, driven by biologics. Alina device gained European approval; divestiture of non-core Balda C. Brewer completed. Full-year guidance raised modestly on currency tailwinds and organic growth. Q2 FY26 Alina approvals in multiple European countries; North American approvals expected H2 2026. Fishers (US) and Latina (Italy) expansion on track. Analysts pushed on segment growth attribution (GLP vs. non-GLP biologics), Alina upside, and Engineering stabilization. Management emphasized biologics as durable tailwind beyond single GLP class and highlighted approvals as catalyst for biosimilar validation. Engineering margins improved 370 bps despite revenue decline; optimization plan credited. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Conestoga Capital Advisors, LLC | 2.57% |
| Neuberger Berman Group LLC | 2.06% |
| TimesSquare Capital Management, LLC | 1.27% |
| Van Berkom and Associates Inc | 1.09% |
| Artisan Partners Limited Partnership | 0.95% |
| BAMCO Inc | 0.91% |
| Morgan Stanley - Brokerage Accounts | 0.48% |
| Crédit Agricole S.A. | 0.48% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue rose 8% year over year to €302 million, unchanged at constant currency. • Adjusted EBITDA increased 21% to €78.7 m | 2026-08-06 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Revenue increased 7.3% year over year to EUR 302,003 thousand in Q2 2026, from EUR 280,037 thousand; first-half revenue rose 7.3% | 2026-08-04 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue rose 8% year over year to €302M, driven by 9% growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segme | 2026-08-04 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue increased 8% year over year to €302.0 million. • High-value solutions revenue increased 16% to €135.9 million, re | 2026-08-04 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • The document is a Form 6-K filing by Stevanato Group S.p.A., dated June 5, 2026. • It incorporates a press release dated June 3, | 2026-06-05 |
| Quarterly results (6-K) · Q1 2026 HEADLINE NUMBERS • Q1 2026 revenue was €273.574 million, up from €256.596 million in Q1 2025, an increase of approximately 6.6%. • Gross profit incr | 2026-05-07 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Stevanato Group filed its Form 20-F for the fiscal year ended December 31, 2025, using IFRS Accounting Standards. • The company h | 2026-03-04 |
| Quarterly results (6-K) · Q3 2025 HEADLINE NUMBERS • Q3 2025 revenue was EUR 303,167 thousand, up from EUR 277,867 thousand in Q3 2024. • Nine-month revenue was EUR 839,800 thousand, | 2025-11-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.06 / share ex-date Jun 11, 2026 · pay Jul 29, 2026 | 2026-06-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Stevanato Group SpA — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.